Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Glutamate SCHEMBL29172230 | 1.00 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL28543045 | 0.98 | CA1 (0.50) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL5604919 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL377275 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL1457846 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL23611029 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL4607698 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL21638309 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL20593979 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D | |
| D-Glutamate SCHEMBL3747279 | 0.95 | CA1 (0.48) | CA1BBOX1GRM8GRM6GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11241455-B2 | Methods of treating disease by metabolic control of T-cell differentiation | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2022-02-08 | — | — | US | disclosed |
| EP-2802646-B1 | MODIFIED BORDETELLA PERTUSSIS STRAINS | BIONET-ASIA CO LTD (TH) | 2017-05-10 | — | — | EP | disclosed |
| US-9187754-B2 | Modified Bordetella pertussis strains | BIONET-ASIA, CO. LTD. (TH) | 2015-11-17 | — | — | US | disclosed |
| EP-2802646-A1 | MODIFIED BORDETELLA PERTUSSIS STRAINS | Bionet-Asia Co. Ltd (TH) | 2014-11-19 | — | — | EP | disclosed |
| US-20140302558-A1 | MODIFIED BORDETELLA PERTUSSIS STRAINS | BIONET-ASIA, CO. LTD. (TH) | 2014-10-09 | — | — | US | disclosed |
| EP-2758484-A1 | USE OF GLUTAMATE FOR MICROBIAL ENHANCED OIL RECOVERY | E. I. Du Pont de Nemours and Company (US) | 2014-07-30 | — | — | EP | disclosed |
| CN-103814105-A | Use of glutamate for microbial enhanced oil recovery | DU PONT | 2014-05-21 | — | — | CN | disclosed |
| WO-2013141823-A1 | MODIFIED BORDETELLA PERTUSSIS STRAINS | BIONET-ASIA, CO. LTD (TH) | 2013-09-26 | — | — | WO | disclosed |
| US-20130075085-A1 | USE OF GLUTAMATE FOR MICROBIAL ENHANCED OIL RECOVERY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-03-28 | — | — | US | disclosed |
| WO-2013044218-A1 | USE OF GLUTAMATE FOR MICROBIAL ENHANCED OIL RECOVERY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20060014162-A1 | Identification and characterization of racemases, definition of protein signatures, and a test for detecting D-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase | INSTITUT PASTEUR | 2006-01-19 | — | — | US | disclosed |
| EP-1592788-A2 | IDENTIFICATION AND CHARACTERIZATION OF RACEMASES, DEFINITION OF PROTEIN SIGNATURES, AND A TEST FOR DETECTING D-AMINO ACID AND FOR SCREENING MOLECULES CAPABLE OF INHIBITING THE ACTIVITY OF RACEMASE, ESPECIALLY PROLINE RACEMASE | INSTITUT PASTEUR (FR) | 2005-11-09 | — | — | EP | disclosed |
| EP-1157000-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER LAMBERT CO (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004072223-A2 | IDENTIFICATION AND CHARACTERIZATION OF RACEMASES, DEFINITION OF PROTEIN SIGNATURES, AND A TEST FOR DETECTING D-AMINO ACID AND FOR SCREENING MOLECULES CAPABLE OF INHIBITING THE ACTIVITY OF RACEMASE, ESPECIALLY PROLINE RACEMASE | INSTITUT PASTEUR (FR) | 2004-08-26 | — | — | WO | disclosed |
| EP-1157000-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER-LAMBERT COMPANY (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2001042191-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF DIABETIC RETINOPATHY | WARNER-LAMBERT COMPANY (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2000061763-A2 | PROTEINS RELATED TO GABA METABOLISM | UNIVERSITY OF GUELPH (CA) | 2000-10-19 | — | — | WO | disclosed |
| US-6083728-A | PREPARING GLUTAMIC ACID; CULTURING WILD TYPE MICROORGANISM IN NUTRIENT BROTH WITH METHANOL, BIOTIN AND COPPER, RECOVERING THE EXCRETED GLUTAMIC ACID FROM THE NUTRIENT BROTH | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2000-07-04 | — | — | US | disclosed |
| WO-1999020785-A1 | PRODUCTION OF GLUTAMATE USING WILD TYPE BACILLUS METHANOLICUS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1999-04-29 | — | — | WO | disclosed |
| US-5597548-A | METABOLISM TO ACETYL COENZYME A; MEASURING GLUTAMATE ENRICHMENT PATTERN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1997-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014162-A1 | Identification and characterization of racemases, definition of protein signatures, and a test for detecting D-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase | SRR, METAP1, RNPEP | CA1 1499/4885BBOX1 1271/4885GRM8 3118/4885 |
| US-11241455-B2 | Methods of treating disease by metabolic control of T-cell differentiation | GOT1, IL17A, OGDH | CA1 830/4885BBOX1 319/4885GRM8 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.